News Headlines

  1. Onconova Achieves Over 75 Percent Of Planned Enrollment In Pivotal Phase 3 INSPIRE Study Of Rigosertib In Myelodysplastic Syndromes

    Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer today announced that it has surpassed the 75 percent enrollment milestone in its pivotal Phase 3 trial of rigosertib for the potential treatment of high-risk myelodysplastic syndromes (HR-MDS), a study known as INSPIRE.

  2. Developing Vaccines And Therapies For The Highly Pathogenic Nipah And Hendra Viruses

    Bethesda, MD, March 20, 2019 – The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), along with Uniformed Services University of the Health Sciences (USU), Profectus Biosciences, Inc., the Vanderbilt University Medical Center, Mapp Biopharmaceutical, Inc., and the University of Texas Medical Branch (UTMB) have been awarded up to $24.5 million to advance treatments for two lethal henipaviruses.

  3. Conatus Announces Top-line Results From ENCORE-NF Phase 2b Clinical Trial In NASH Fibrosis

    Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and liver fibrosis. The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement with no worsening of steatohepatitis compared with placebo at week 72.

  4. Aptevo Therapeutics Begins Phase 1 Clinical Trial Of APVO210 A Novel Bispecific Antibody For The Treatment Of Autoimmune And Inflammatory Diseases

    Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, announced today that it has commenced dosing in a Phase 1 clinical trial of APVO210, a novel bispecific antibody candidate built on Aptevo’s ADAPTIR™ therapeutic protein platform which is being developed to treat autoimmune and inflammatory diseases.

  5. ArcelorMittal Kryvyi Rih Will Build A New Tube Furnace And Continue The Reconstruction Of Sinter Shop No. 2

    Recently, ArcelorMittal Kryvyi Rih presented at public hearings environmental impact assessment reports for two investment projects - reconstruction of a complex of buildings and structures of sintering machines No. 1-3 of the second aglo shop and construction of a tube furnace in the benzene department capture coke production

  6. WCG Introduces A Transformational Solution For Clinical Research Sites

    WIRB-Copernicus Group® (WCG™) introduces WCG SiteReady™, a first-of-its-kind solution aimed at increasing the efficiency and profitability of clinical research for institutions and independent research sites. WCG’s newest offering helps researchers to optimize their performance, gain a competitive edge, and attract more opportunities for externally-funded clinical trials.

  7. CRF Bracket Supports Remote Consenting For Virtual Clinical Studies With Latest Release Of Its Integrated eConsent Solution

    CRF Bracket announced a new release of TrialConsent®, the latest version of its revolutionary eConsent solution, with enhanced capabilities to support remote consenting in virtual clinical trials.

  8. Crinetics Pharmaceuticals Doses First Patients In Phase 2 Clinical Trials Of CRN00808 For Acromegaly

    Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the dosing of the first patients in the ACROBAT EVOLVE and EDGE trials for CRN00808 in patients with acromegaly.

  9. Rain Therapeutics Announces First Patient Dosed In Phase 2 Trial Of Tarloxotinib For The Treatment Of Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Or HER2-Activating Mutations

    Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced that it has dosed the first patient in its Phase 2 clinical trial of tarloxotinib (Tarlox).

  10. CytoDyn Reaches Historical Milestone, Submits First Of Three Sections Of BLA To FDA For Leronlimab (PRO 140) As A Combination Therapy For HIV

    CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has filed with the U.S. Food and Drug Administration (FDA) the non-clinical portion of its Biologics License Application (BLA) using the FDA’s Rolling Review process.